Home
Trevena

Trevena Market Share Analysis for June 2026

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has four novel and differentiated drug development…

Health

Domaintrevena.com

Year Founded2007

Employees51 - 200

Annual Revenue< $1M

Trevena

Trevena (including company regionals)

trevena.com

See more website traffic and engagement information

Total visits to Trevena's top domains

Understand Trevena market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

trevena.com2.8K

See more with Sales Intelligence

Avg. visit duration in Trevena's top domains

Analyze Trevena engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

trevena.com00:00:36

See more with Sales Intelligence

Avg. pageviews on Trevena's top domains

See how Trevena keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

trevena.com1.76

See more with Sales Intelligence

Trevena top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Trevena

These are the website technologies, by industry, used by Trevena top domains

Payment & Currencies (7)

Cart Functionality

Widget (3)

reCAPTCHA

Business Solutions (2)

FreshWorks

Content Management System (2)

Web Dot Com

More Technologies

9

See all

News & Signals from Trevena

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsTrevena, Inc. receives financing of $4M.Trevena announces the closing of $4 million concurrent private placement and warrant exercise.

NewsTrevena, Inc. launches TRV045 Data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS Target Engagement.Trevena announces preliminary TRV045 Data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS Target Engagement.

NewsTrevena, Inc. launches topline OLINVYK data from the ARTEMIS study.Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, announced new topline OLINVYK data from the ARTEMIS study.